Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral Care Innovation Rooted in Trans-Pacific Alder Research

Dr. Oregonin Inc. announced that it has completed U.S. Food and Drug Administration (FDA) registration for OLTIS DENTAL-X, paving the way for its official commercial entry into the North American oral-care market. The product's authorization...

Aptar Pharma Launched Premia™ Precision, Establishing a New Quality Standard for Demanding Injectable Therapies

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, announced the launch of Premia™ Precision, a new quality standard for elastomer components, designed to support sensitive and high-value injectable...

Hovione to Bring Next-Generation Continuous Tableting to the U.S. with the World’s First ConsiGma® CDC Flex Commissioning

Hovione, a globally integrated pharmaceutical contract development and manufacturing organization (CDMO), announced it will commission the world's first ConsiGma® CDC Flex – a next generation continuous tableting line – at its East Windsor, New...

Niagen Bioscience Puts 25 Years of NAD+ Science Behind “Don’t Get Old. Age Better.®” — a New Campaign for Its Niagen® Brand Featuring Legendary Surfer Kelly Slater

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of “Don't Get Old. Age Better.®,” a new brand campaign for its Niagen® (patented...

Upsher-Smith Launched Fluvoxamine Maleate Extended-Release Capsules

Upsher-Smith Laboratories, LLC a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), today announced the recent launch of Fluvoxamine Maleate Extended-Release Capsules in 100 mg and 150 mg strengths. According to IQVIA, the...

Cronus Pharma Announces the Launch of Florfinasone™ Otic for the Treatment of Otitis Externa in Dogs

Cronus Pharma LLC, a fully integrated animal health company, announced the launch of Florfinasone Otic (florfenicol, terbinafine, mometasone furoate), an FDA-approved product indicated for the treatment of otitis externa in dogs associated with...

LEVEL Relief Protab Reduced Everyday Aches and Pain in an Independent 29-Day Study

LEVEL, a science-driven cannabinoid company, announced results from an independent 29-day real-world study of its Relief Protab, conducted in partnership with third-party research firm MoreBetter. Across 427 adults with ongoing aches and pain, the...

FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH

Merck known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3...

StimCardio’s NeuroPulse Study Reports a Substantial Reduction in Recurrent Atrial Fibrillation Events Following Ablation Using Non-Invasive Wearable Neuromodulation

StimCardio Medical announced positive results from the randomized, double-blind, sham-controlled NeuroPulse pilot study evaluating non-invasive median nerve stimulation (MNS) following atrial fibrillation (AF) ablation. The study was selected for...

Scitara Appoints Mike Tarselli as Chief Strategy Officer to Drive Growth in Lab Intelligence

Scitara, the Lab Connectivity and AI platform company serving the life sciences and biopharma industries, announced a new strategic direction for the company alongside the appointment of Mike Tarselli, Ph.D., MBA, as Chief Strategy Officer. The...

Stasis Introduces the First Day-and-Night Supplement System Built for Children Who Take Stimulants

Stasis, the company behind the first supplement system designed to be taken alongside stimulants, today introduced Stasis Kids, a day-and-night nutritional supplement system made for children ages 6 to 17. In 2023, 16.5 million people in the...

Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing

Asahi Kasei Bioprocess, a subsidiary of diversified global company Asahi Kasei, will unveil the VANTIJ® SU-VFC Benchtop at Bioprocess International East (BPI EAST) 2026. This new VANTIJ® SU-VFC is a small-format system designed to deliver...

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

SQ Innovation announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) Level II code, J1946 ("Injection, furosemide (Lasix ONYU), 1 mg"), for its product Lasix® ONYU...

Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

Jarrow Formulas®, a leading formulator and supplier of science-backed nutritional supplements, announced the launch of two new products, expanding its portfolio with targeted nutritional support: Jarrow Formulas® Gut & Protein Optimizer, designed...

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology. The new biowearable is designed to alert people...

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

Acadia Pharmaceuticals Inc. announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and...

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Laboratories, LLC a subsidiary of Bora Pharmaceuticals Co., Ltd. (6472.TW and BORAY.OTCQX), announced the recent launch of Glatiramer Acetate Injection in 20 mg/mL and 40 mg/mL strengths, adding to the Company's portfolio of complex...

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharmaceuticals Ireland's first EU GMP-certified manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs), announced that its plant-derived dronabinol API, WaterClear THC™, is now available across the United...

Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

Neurolief, a neuroscience-driven medical technology company developing brain neuromodulation therapies for mental health and neurological conditions, is bringing two prescription therapies to U.S. veterans through a new Department of Veterans...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...